Emerging therapeutic targets in bladder cancer

Benedito A. Carneiro*, Joshua J. Meeks, Timothy M. Kuzel, Mariana Scaranti, Sarki A. Abdulkadir, Francis J. Giles

*Corresponding author for this work

Research output: Contribution to journalReview article

64 Citations (Scopus)

Abstract

Treatment of muscle invasive urothelial bladder carcinoma (BCa) remains a major challenge. Comprehensive genomic profiling of tumors and identification of driver mutations may reveal new therapeutic targets. This manuscript discusses relevant molecular drivers of the malignant phenotype and agents with therapeutic potential in BCa. Small molecule pan-FGFR inhibitors have shown encouraging efficacy and safety results especially among patients with activating FGFR mutations or translocations. mTOR inhibitors for patients with TSC1 mutations and concomitant targeting of PI3K and MEK represent strategies to block PI3K/AKT/mTOR pathway. Encouraging preclinical results with ado-trastuzumab emtansine (T-DM1) exemplifies a new potential treatment for HER2-positive BCa along with innovative bispecific antibodies. Inhibitors of cell cycle regulators (aurora kinase, polo-like kinase 1, and cyclin-dependent kinase 4) are being investigated in combination with chemotherapy. Early results of clinical studies with anti-CTLA4 and anti-PDL1 are propelling immune modulating drugs to the forefront of emerging treatments for BCa. Collectively, these novel therapeutic targets and treatment strategies hold promise to improve the outcome of patients afflicted with this malignancy.

Original languageEnglish (US)
Pages (from-to)170-178
Number of pages9
JournalCancer Treatment Reviews
Volume41
Issue number2
DOIs
StatePublished - Feb 1 2015

Fingerprint

Urinary Bladder Neoplasms
Urinary Bladder
Carcinoma
Phosphatidylinositol 3-Kinases
Mutation
Therapeutics
Aurora Kinases
Cyclin-Dependent Kinase 4
Bispecific Antibodies
Mitogen-Activated Protein Kinase Kinases
Combination Drug Therapy
Neoplasms
Cell Cycle
Phenotype
Safety
Muscles
Pharmaceutical Preparations

Keywords

  • Bladder cancer
  • Immunotherapy
  • Targeted therapy
  • Treatment
  • Urothelial bladder carcinoma

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Carneiro, Benedito A. ; Meeks, Joshua J. ; Kuzel, Timothy M. ; Scaranti, Mariana ; Abdulkadir, Sarki A. ; Giles, Francis J. / Emerging therapeutic targets in bladder cancer. In: Cancer Treatment Reviews. 2015 ; Vol. 41, No. 2. pp. 170-178.
@article{be3195a444694b9daa7ac8c7951d6aa4,
title = "Emerging therapeutic targets in bladder cancer",
abstract = "Treatment of muscle invasive urothelial bladder carcinoma (BCa) remains a major challenge. Comprehensive genomic profiling of tumors and identification of driver mutations may reveal new therapeutic targets. This manuscript discusses relevant molecular drivers of the malignant phenotype and agents with therapeutic potential in BCa. Small molecule pan-FGFR inhibitors have shown encouraging efficacy and safety results especially among patients with activating FGFR mutations or translocations. mTOR inhibitors for patients with TSC1 mutations and concomitant targeting of PI3K and MEK represent strategies to block PI3K/AKT/mTOR pathway. Encouraging preclinical results with ado-trastuzumab emtansine (T-DM1) exemplifies a new potential treatment for HER2-positive BCa along with innovative bispecific antibodies. Inhibitors of cell cycle regulators (aurora kinase, polo-like kinase 1, and cyclin-dependent kinase 4) are being investigated in combination with chemotherapy. Early results of clinical studies with anti-CTLA4 and anti-PDL1 are propelling immune modulating drugs to the forefront of emerging treatments for BCa. Collectively, these novel therapeutic targets and treatment strategies hold promise to improve the outcome of patients afflicted with this malignancy.",
keywords = "Bladder cancer, Immunotherapy, Targeted therapy, Treatment, Urothelial bladder carcinoma",
author = "Carneiro, {Benedito A.} and Meeks, {Joshua J.} and Kuzel, {Timothy M.} and Mariana Scaranti and Abdulkadir, {Sarki A.} and Giles, {Francis J.}",
year = "2015",
month = "2",
day = "1",
doi = "10.1016/j.ctrv.2014.11.003",
language = "English (US)",
volume = "41",
pages = "170--178",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "2",

}

Emerging therapeutic targets in bladder cancer. / Carneiro, Benedito A.; Meeks, Joshua J.; Kuzel, Timothy M.; Scaranti, Mariana; Abdulkadir, Sarki A.; Giles, Francis J.

In: Cancer Treatment Reviews, Vol. 41, No. 2, 01.02.2015, p. 170-178.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Emerging therapeutic targets in bladder cancer

AU - Carneiro, Benedito A.

AU - Meeks, Joshua J.

AU - Kuzel, Timothy M.

AU - Scaranti, Mariana

AU - Abdulkadir, Sarki A.

AU - Giles, Francis J.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Treatment of muscle invasive urothelial bladder carcinoma (BCa) remains a major challenge. Comprehensive genomic profiling of tumors and identification of driver mutations may reveal new therapeutic targets. This manuscript discusses relevant molecular drivers of the malignant phenotype and agents with therapeutic potential in BCa. Small molecule pan-FGFR inhibitors have shown encouraging efficacy and safety results especially among patients with activating FGFR mutations or translocations. mTOR inhibitors for patients with TSC1 mutations and concomitant targeting of PI3K and MEK represent strategies to block PI3K/AKT/mTOR pathway. Encouraging preclinical results with ado-trastuzumab emtansine (T-DM1) exemplifies a new potential treatment for HER2-positive BCa along with innovative bispecific antibodies. Inhibitors of cell cycle regulators (aurora kinase, polo-like kinase 1, and cyclin-dependent kinase 4) are being investigated in combination with chemotherapy. Early results of clinical studies with anti-CTLA4 and anti-PDL1 are propelling immune modulating drugs to the forefront of emerging treatments for BCa. Collectively, these novel therapeutic targets and treatment strategies hold promise to improve the outcome of patients afflicted with this malignancy.

AB - Treatment of muscle invasive urothelial bladder carcinoma (BCa) remains a major challenge. Comprehensive genomic profiling of tumors and identification of driver mutations may reveal new therapeutic targets. This manuscript discusses relevant molecular drivers of the malignant phenotype and agents with therapeutic potential in BCa. Small molecule pan-FGFR inhibitors have shown encouraging efficacy and safety results especially among patients with activating FGFR mutations or translocations. mTOR inhibitors for patients with TSC1 mutations and concomitant targeting of PI3K and MEK represent strategies to block PI3K/AKT/mTOR pathway. Encouraging preclinical results with ado-trastuzumab emtansine (T-DM1) exemplifies a new potential treatment for HER2-positive BCa along with innovative bispecific antibodies. Inhibitors of cell cycle regulators (aurora kinase, polo-like kinase 1, and cyclin-dependent kinase 4) are being investigated in combination with chemotherapy. Early results of clinical studies with anti-CTLA4 and anti-PDL1 are propelling immune modulating drugs to the forefront of emerging treatments for BCa. Collectively, these novel therapeutic targets and treatment strategies hold promise to improve the outcome of patients afflicted with this malignancy.

KW - Bladder cancer

KW - Immunotherapy

KW - Targeted therapy

KW - Treatment

KW - Urothelial bladder carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84921651021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921651021&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2014.11.003

DO - 10.1016/j.ctrv.2014.11.003

M3 - Review article

C2 - 25498841

AN - SCOPUS:84921651021

VL - 41

SP - 170

EP - 178

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 2

ER -